Description
Gilead Sciences’ $1.5 Billion Medicare Threat — Is Wall Street Missing the Risk?
Gilead Sciences, Inc. reported a third quarter 2026 performance marked by notable growth across its core therapeutic areas, alongside continued advancement of its diversified pipeline. Base business sales increased 16% year-over-year to $8.2 billion, the strongest growth since 2015, driven mainly by HIV treatments and prevention products, oncology, and liver disease offerings. Total product sales, including Veklury, a COVID-19 treatment, rose 13% year-over-year to $8.3 billion. HIV revenues were up 18% year-over-year to $6.2 billion, driven by strong demand, favorable pricing, and inventory dynamics. Key HIV products such as Biktarvy, Descovy, and Yeztugo contributed significantly, with Biktarvy achieving an all-time high U.S. market share and Yeztugo solidifying its position as the leading long-acting injectable option in HIV prevention. The HIV prevention segment’s sales nearly doubled, with combined market share for Yeztugo and Descovy at 50%.



